2022 was about ex­e­cu­tion. Now will Am­gen's growth strat­e­gy prove its worth?

Four of Am­gen’s top drugs all saw record sales last quar­ter and strong an­nu­al growth, but the Cal­i­for­nia-based bio­phar­ma com­pa­ny still has more than a cou­ple re­main­ing ques­tion marks to re­solve mov­ing in­to 2023 and be­yond.

In its Q4 earn­ings re­port yes­ter­day, ex­ecs high­light­ed the suc­cess of its os­teo­poro­sis drug Pro­lia (12% sales growth in 2022 vs. 2021), its oth­er bone drug Eveni­ty (48% an­nu­al sales growth), its cho­les­terol in­jec­tion Repatha (16% sales growth over the year), and its mi­graine drug Aimovig (31% an­nu­al sales growth).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER